Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Saturday, December 15, 2018 · 471,224,996 Articles · 3+ Million Readers

Russia In-Focus: Cardium, bioRASI Partner On Generx Study

June 11, 2010 (FinancialWire) (Go to for all of today’s featured news.) — Cardium Therapeutics (AMEX: CXM) said that it has entered into a master services agreement with bioRASI, a contract research organization, to assist Cardium in the conduct of a planned late-stage clinical study and commercialization activities for Cardium's Generx drug candidate in Russia and affiliated jurisdictions, as well as in potentially other newly industrializing markets. Under the terms of the agreement, bioRASI will assist Cardium to conduct a late-stage clinical study to evaluate the efficacy and safety of Cardium's Generx product candidate at up to three leading medical centers in Moscow and to assist the company in commercialization activities in these international markets.

The Generx clinical study is scheduled to be initiated in the second half of this year and will be a randomized, controlled, parallel-group, multicenter study to evaluate the safety and efficacy of Generx using adenosine SPECT imaging of myocardial blood flow in patients with stable angina pectoris.

The primary endpoint will be the change in reversible perfusion defect size as measured by adenosine SPECT imaging, which is directly analogous to that successfully used in a Phase 2a clinical study of Generx.

Cardium believes that Generx could potentially be developed as a cost effective front-line therapy for patients with coronary artery disease in the large markets of newly-industrializing countries who often do not have access to costly advanced care procedures such as coronary angioplasty and stenting, or cardiac bypass surgery, which in the U.S. can cost $50,000 to $100,000 over a five-year period following initial treatment.

Generx is a DNA-based angiogenic growth factor therapeutic product candidate representing a new class of cardiovascular biologics as a treatment for patients with advanced coronary artery disease.

California-based Cardium is focused on the acquisition and strategic development of bio-medical product opportunities and businesses. The firm’s investment portfolio includes the Tissue Repair Co. and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications.  

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate ( written by FIRST Research Consortium ( member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at and Additional resources for investors are also accessible via the FinancialWire(tm) website (at Contact FinancialWire(tm) directly via

[hlmsmlh] [biomedphrm] [prtnrshpsphs] [ftrdnwswnd] [ntrntnlcmpnsbsnss] [estrnblclbnr] [rssnssrsn]

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release